Pureos Bioventures is a venture capital firm that focuses on early-stage investments in the life sciences sector, particularly in therapeutic start-ups developing innovative treatments for serious diseases.

Pureos Bioventures is a venture capital fund, which invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and
neuroscience. Pureos has built a team with deep investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases.

Corlieve Therapeutics

Lava Therapeutics

Acrivon Therapeutics

Pureos Bioventures

Our portfolio company VICO Therapeutics B.V. closed their Series B financing of EUR 54mn to advance the clinical development of their lead program VO659 in spinocerebellar ataxia types 3 and 1 and Huntington’s disease.
Congratulations to the team!
 
We are looking forward continuing the journey to bring innovation to patients with rare neurological disease.

https://lnkd.in/eiQ2xBX4

Our portfolio company LAVA Therapeutics N.V. announces a collaboration with Merck & Co., Inc. to evaluate Lava-1207 in combination with pembrolizumab. This cooperation will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with prostate cancer (mCRPC).
We are looking forward continuing the journey to bring new therapies to patients with mCRPC.

https://lnkd.in/eBNc9ZjA 

Pureos Bioventures portfolio company AM-Pharma started testing ilofotase alfa, as a preventive treatment for cardiac surgery-associated renal damage in a clincal Phase 2 study. A high medical need indication. Fingers crossed that ilofotase will help to prevent CSA-RD!

https://lnkd.in/eykpXE5R

Start your year with listening to the latest episode of The Drug Discovery World Podcast! Manfred Ruediger, CEO of our portfolio company Ariceum Therapeutics talks about their pipeline of radiopharmaceutical drugs for cancer patients and the future for the company.
 
Do not miss:
https://lnkd.in/eGcPJwGK

COM:PUREOSBIO

Pureos Bioventures

Analysis Not Available